RU2018143994A - Доноры нитроксила с улучшенным терапевтическим индексом - Google Patents
Доноры нитроксила с улучшенным терапевтическим индексом Download PDFInfo
- Publication number
- RU2018143994A RU2018143994A RU2018143994A RU2018143994A RU2018143994A RU 2018143994 A RU2018143994 A RU 2018143994A RU 2018143994 A RU2018143994 A RU 2018143994A RU 2018143994 A RU2018143994 A RU 2018143994A RU 2018143994 A RU2018143994 A RU 2018143994A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- alkyl
- intravenous administration
- pharmaceutical composition
- Prior art date
Links
- 231100001274 therapeutic index Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 50
- 238000001990 intravenous administration Methods 0.000 claims 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361754237P | 2013-01-18 | 2013-01-18 | |
| US61/754,237 | 2013-01-18 | ||
| US201361782781P | 2013-03-14 | 2013-03-14 | |
| US61/782,781 | 2013-03-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134581A Division RU2676277C2 (ru) | 2013-01-18 | 2014-01-17 | Доноры нитроксила с улучшенным терапевтическим индексом |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018143994A true RU2018143994A (ru) | 2019-01-16 |
Family
ID=50064795
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018143994A RU2018143994A (ru) | 2013-01-18 | 2014-01-17 | Доноры нитроксила с улучшенным терапевтическим индексом |
| RU2015134581A RU2676277C2 (ru) | 2013-01-18 | 2014-01-17 | Доноры нитроксила с улучшенным терапевтическим индексом |
| RU2015134583A RU2684916C2 (ru) | 2013-01-18 | 2014-01-17 | Фармацевтические композиции, содержащие доноры нитроксила |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134581A RU2676277C2 (ru) | 2013-01-18 | 2014-01-17 | Доноры нитроксила с улучшенным терапевтическим индексом |
| RU2015134583A RU2684916C2 (ru) | 2013-01-18 | 2014-01-17 | Фармацевтические композиции, содержащие доноры нитроксила |
Country Status (29)
| Country | Link |
|---|---|
| US (13) | US10245249B2 (https=) |
| EP (5) | EP3427728B1 (https=) |
| JP (5) | JP6449171B2 (https=) |
| KR (2) | KR102177899B1 (https=) |
| CN (4) | CN105073105B (https=) |
| AU (5) | AU2014207408C1 (https=) |
| BR (2) | BR112015017241B1 (https=) |
| CA (2) | CA2898445C (https=) |
| CY (3) | CY1120535T1 (https=) |
| DK (3) | DK2945620T3 (https=) |
| ES (4) | ES2705240T3 (https=) |
| HK (1) | HK1251170B (https=) |
| HR (3) | HRP20180121T1 (https=) |
| HU (3) | HUE036589T2 (https=) |
| IL (4) | IL239906B (https=) |
| LT (3) | LT2945621T (https=) |
| MX (2) | MX373176B (https=) |
| NZ (4) | NZ748769A (https=) |
| PL (3) | PL2945620T3 (https=) |
| PT (3) | PT2945620T (https=) |
| RS (3) | RS58174B1 (https=) |
| RU (3) | RU2018143994A (https=) |
| SG (6) | SG10201802862WA (https=) |
| SI (3) | SI2945621T1 (https=) |
| SM (3) | SMT201900575T1 (https=) |
| TR (1) | TR201802211T4 (https=) |
| TW (3) | TWI712409B (https=) |
| WO (2) | WO2014113700A1 (https=) |
| ZA (2) | ZA201505090B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030356B2 (en) | 2006-03-17 | 2011-10-04 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| JP6177246B2 (ja) | 2011-10-17 | 2017-08-09 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体 |
| SG10201802862WA (en) * | 2013-01-18 | 2018-05-30 | Cardioxyl Pharmaceuticals Inc | Pharmaceutical compositions comprising nitroxyl donors |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
| EP3148972B1 (en) | 2014-05-27 | 2019-08-21 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| JP2018526448A (ja) | 2015-09-07 | 2018-09-13 | 浙江華海薬業股▲フン▼有限公司 | 一酸化窒素を放出可能なプロドラッグ分子 |
| US10723704B2 (en) | 2015-10-19 | 2020-07-28 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| KR20180070672A (ko) | 2015-10-19 | 2018-06-26 | 카르디옥실 파마슈티칼스 인코포레이티드 | 니트록실 공여자로서의 n-히드록실술폰아미드 유도체 |
| EP3490975B1 (en) | 2016-07-28 | 2021-05-05 | The Johns Hopkins University | O-substituted hydroxamic acids |
| WO2018128999A1 (en) * | 2017-01-03 | 2018-07-12 | Cardioxyl Pharmaceuticals, Inc. | Method of administering nitroxyl donating compounds |
| JP7266531B2 (ja) * | 2017-04-18 | 2023-04-28 | ジェンフィ | エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ |
| CN116283762B (zh) * | 2023-03-28 | 2025-08-12 | 昆山市第一人民医院 | 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法 |
| WO2025043108A1 (en) * | 2023-08-23 | 2025-02-27 | Bristol -Myers S Quibb Company | Co-crystals of nitroxyl donating compounds |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017976A (en) | 1911-08-25 | 1912-02-20 | Rudolph Koch | Automatic mail-bag catcher and deliverer. |
| US1021340A (en) | 1911-10-14 | 1912-03-26 | William A Scott | Means for attaching binding-posts to dry batteries. |
| US3751255A (en) | 1972-03-24 | 1973-08-07 | Eastman Kodak Co | Photosensitive and thermosensitive element, composition and process |
| JPS567710A (en) | 1979-06-28 | 1981-01-27 | Sansho Seiyaku Kk | Whitening cosmetic |
| US4539321A (en) | 1981-10-26 | 1985-09-03 | William H. Rorer, Inc. | 5-Diaza-aryl-3-substituted pyridone compounds |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| US4663351A (en) | 1985-08-23 | 1987-05-05 | Berlex Laboratories, Inc. | Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| JPH01221371A (ja) | 1988-02-29 | 1989-09-04 | Hokko Chem Ind Co Ltd | 環状オキシアミン誘導体の製造方法 |
| JPH01221372A (ja) | 1988-03-01 | 1989-09-04 | Hokko Chem Ind Co Ltd | 環状アシルヒドロキシルアミン誘導体 |
| JPH0221372A (ja) | 1988-07-08 | 1990-01-24 | Sharp Corp | はんだ付検査装置 |
| JPH0828240B2 (ja) | 1990-05-25 | 1996-03-21 | 矢崎総業株式会社 | 電線相互の圧着接続構造及び圧着接続方法 |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| JPH04321671A (ja) | 1991-04-17 | 1992-11-11 | Mitsubishi Petrochem Co Ltd | カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤 |
| JPH09507672A (ja) * | 1994-01-19 | 1997-08-05 | ビイク ネダーラント ベスローテン フェンノートシャップ | ニトロキシ基含有ベンジルアミン誘導体及び循環器疾患並びに眼内圧増加の治療のためのその使用 |
| US6156728A (en) * | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| JPH10142729A (ja) | 1996-11-05 | 1998-05-29 | Fuji Photo Film Co Ltd | 熱現像画像記録材料 |
| AU741180B2 (en) | 1997-10-24 | 2001-11-22 | Shionogi & Co., Ltd. | Antirheumatic |
| EP0930302B1 (en) * | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| WO1999063385A1 (en) | 1998-06-04 | 1999-12-09 | Board Of Regents, The University Of Texas System | Digital optical chemistry micromirror imager |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| JP2002072459A (ja) | 2000-08-28 | 2002-03-12 | Toyo Gosei Kogyo Kk | 光酸発生剤及びそれを含有する感光性樹脂組成物 |
| JP2004517892A (ja) * | 2000-12-13 | 2004-06-17 | ワイス | β−アミロイド産生の複素環スルホンアミド阻害剤 |
| EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| GB0114223D0 (en) | 2001-06-12 | 2001-08-01 | Ici Plc | Catalytic oxidation process |
| US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US6936639B2 (en) | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2005074598A2 (en) | 2004-01-30 | 2005-08-18 | Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
| WO2006043965A1 (en) | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| EP1846439A2 (en) | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| US20090298795A1 (en) | 2005-06-23 | 2009-12-03 | The Johns Hopins University | Thiol-Sensitive Positive Inotropes |
| US8030356B2 (en) | 2006-03-17 | 2011-10-04 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| US7696373B2 (en) | 2006-04-13 | 2010-04-13 | Wake Forest University Health Sciences | C-nitroso-derived nitroxyl donors |
| CN104119310B (zh) | 2007-09-26 | 2017-04-12 | 约翰斯霍普金斯大学 | 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物 |
| EP3067352A3 (en) | 2008-05-07 | 2016-10-19 | Cardioxyl Pharmaceuticals Inc. | Novel nitroso compounds as nitroxyl donors and methods of use thereof |
| US20110160200A1 (en) | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| CN105130855B (zh) | 2009-12-07 | 2018-05-25 | 约翰斯霍普金斯大学 | 二酰基化的羟基胺衍生物及其用途 |
| AU2010328234B2 (en) | 2009-12-07 | 2016-05-12 | Cardioxyl Pharmaceuticals, Inc. | N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives |
| JP6177246B2 (ja) | 2011-10-17 | 2017-08-09 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体 |
| JP6306602B2 (ja) | 2012-11-01 | 2018-04-04 | ザ ジョンズ ホプキンス ユニバーシティ | 分子内環化−脱離による制御されたｈｎｏ放出 |
| SG10201802862WA (en) | 2013-01-18 | 2018-05-30 | Cardioxyl Pharmaceuticals Inc | Pharmaceutical compositions comprising nitroxyl donors |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
-
2014
- 2014-01-17 SG SG10201802862WA patent/SG10201802862WA/en unknown
- 2014-01-17 EP EP18190818.7A patent/EP3427728B1/en active Active
- 2014-01-17 JP JP2015553856A patent/JP6449171B2/ja not_active Expired - Fee Related
- 2014-01-17 NZ NZ748769A patent/NZ748769A/en unknown
- 2014-01-17 SI SI201430983T patent/SI2945621T1/sl unknown
- 2014-01-17 EP EP14703010.0A patent/EP2945621B1/en active Active
- 2014-01-17 CN CN201480013565.1A patent/CN105073105B/zh active Active
- 2014-01-17 ES ES14703010T patent/ES2705240T3/es active Active
- 2014-01-17 RU RU2018143994A patent/RU2018143994A/ru unknown
- 2014-01-17 CN CN201910446030.8A patent/CN110179777B/zh active Active
- 2014-01-17 US US14/761,934 patent/US10245249B2/en active Active
- 2014-01-17 HU HUE14703009A patent/HUE036589T2/hu unknown
- 2014-01-17 PT PT147030092T patent/PT2945620T/pt unknown
- 2014-01-17 RU RU2015134581A patent/RU2676277C2/ru active
- 2014-01-17 TW TW107143952A patent/TWI712409B/zh not_active IP Right Cessation
- 2014-01-17 NZ NZ709986A patent/NZ709986A/en unknown
- 2014-01-17 RS RS20181599A patent/RS58174B1/sr unknown
- 2014-01-17 CN CN201480013223.XA patent/CN105142627B/zh active Active
- 2014-01-17 HU HUE17195759A patent/HUE046722T2/hu unknown
- 2014-01-17 BR BR112015017241-5A patent/BR112015017241B1/pt active IP Right Grant
- 2014-01-17 WO PCT/US2014/012089 patent/WO2014113700A1/en not_active Ceased
- 2014-01-17 SM SM20190575T patent/SMT201900575T1/it unknown
- 2014-01-17 MX MX2015009276A patent/MX373176B/es active IP Right Grant
- 2014-01-17 SG SG10201913286PA patent/SG10201913286PA/en unknown
- 2014-01-17 BR BR112015017251-2A patent/BR112015017251B1/pt active IP Right Grant
- 2014-01-17 US US14/158,456 patent/US8987326B2/en active Active
- 2014-01-17 AU AU2014207408A patent/AU2014207408C1/en active Active
- 2014-01-17 CA CA2898445A patent/CA2898445C/en active Active
- 2014-01-17 PL PL14703009T patent/PL2945620T3/pl unknown
- 2014-01-17 ES ES17195759T patent/ES2751922T3/es active Active
- 2014-01-17 DK DK14703009.2T patent/DK2945620T3/en active
- 2014-01-17 EP EP14703009.2A patent/EP2945620B1/en active Active
- 2014-01-17 TW TW103101912A patent/TWI619491B/zh not_active IP Right Cessation
- 2014-01-17 RS RS20180099A patent/RS56968B1/sr unknown
- 2014-01-17 MX MX2015009269A patent/MX363843B/es active IP Right Grant
- 2014-01-17 CA CA2898443A patent/CA2898443C/en active Active
- 2014-01-17 NZ NZ748771A patent/NZ748771A/en unknown
- 2014-01-17 JP JP2015553858A patent/JP6533159B2/ja not_active Expired - Fee Related
- 2014-01-17 PL PL14703010T patent/PL2945621T3/pl unknown
- 2014-01-17 SM SM20180088T patent/SMT201800088T1/it unknown
- 2014-01-17 NZ NZ709985A patent/NZ709985A/en unknown
- 2014-01-17 HR HRP20180121TT patent/HRP20180121T1/hr unknown
- 2014-01-17 SG SG11201505568PA patent/SG11201505568PA/en unknown
- 2014-01-17 PT PT14703010T patent/PT2945621T/pt unknown
- 2014-01-17 CN CN201810074807.8A patent/CN108610312A/zh active Pending
- 2014-01-17 LT LTEP14703010.0T patent/LT2945621T/lt unknown
- 2014-01-17 TW TW103101913A patent/TWI686193B/zh active
- 2014-01-17 AU AU2014207404A patent/AU2014207404B2/en active Active
- 2014-01-17 LT LT17195759T patent/LT3284463T/lt unknown
- 2014-01-17 SG SG10201913441RA patent/SG10201913441RA/en unknown
- 2014-01-17 DK DK14703010.0T patent/DK2945621T3/en active
- 2014-01-17 PT PT171957590T patent/PT3284463T/pt unknown
- 2014-01-17 KR KR1020157022200A patent/KR102177899B1/ko not_active Expired - Fee Related
- 2014-01-17 HR HRP20182144TT patent/HRP20182144T1/hr unknown
- 2014-01-17 ES ES18190818T patent/ES2882279T3/es active Active
- 2014-01-17 EP EP19181338.5A patent/EP3567031A1/en not_active Withdrawn
- 2014-01-17 WO PCT/US2014/012085 patent/WO2014113696A1/en not_active Ceased
- 2014-01-17 SM SM20190027T patent/SMT201900027T1/it unknown
- 2014-01-17 ES ES14703009.2T patent/ES2659969T3/es active Active
- 2014-01-17 KR KR1020157022192A patent/KR102277165B1/ko active Active
- 2014-01-17 EP EP17195759.0A patent/EP3284463B1/en active Active
- 2014-01-17 SG SG10201802855TA patent/SG10201802855TA/en unknown
- 2014-01-17 HU HUE14703010A patent/HUE041861T2/hu unknown
- 2014-01-17 SI SI201430507T patent/SI2945620T1/en unknown
- 2014-01-17 RS RSP20191352 patent/RS59434B1/sr unknown
- 2014-01-17 DK DK17195759T patent/DK3284463T3/da active
- 2014-01-17 LT LTEP14703009.2T patent/LT2945620T/lt unknown
- 2014-01-17 RU RU2015134583A patent/RU2684916C2/ru active
- 2014-01-17 PL PL17195759T patent/PL3284463T3/pl unknown
- 2014-01-17 SI SI201431361T patent/SI3284463T1/sl unknown
- 2014-01-17 SG SG11201505567RA patent/SG11201505567RA/en unknown
- 2014-01-17 TR TR2018/02211T patent/TR201802211T4/tr unknown
-
2015
- 2015-03-07 US US14/641,377 patent/US9156804B2/en active Active
- 2015-07-13 IL IL239906A patent/IL239906B/en active IP Right Grant
- 2015-07-15 IL IL239952A patent/IL239952B/en active IP Right Grant
- 2015-07-15 ZA ZA2015/05090A patent/ZA201505090B/en unknown
- 2015-10-09 US US14/880,173 patent/US9586896B2/en active Active
-
2016
- 2016-07-07 ZA ZA2016/04798A patent/ZA201604798B/en unknown
-
2017
- 2017-01-10 AU AU2017200147A patent/AU2017200147B2/en active Active
- 2017-01-16 JP JP2017005276A patent/JP6311038B2/ja not_active Expired - Fee Related
- 2017-02-13 US US15/430,946 patent/US9968584B2/en active Active
-
2018
- 2018-01-12 CY CY20181100038T patent/CY1120535T1/el unknown
- 2018-04-23 IL IL258882A patent/IL258882A/en active IP Right Grant
- 2018-04-24 US US15/960,993 patent/US10213408B2/en active Active
- 2018-05-09 IL IL25923318A patent/IL259233B/en active IP Right Grant
- 2018-05-09 AU AU2018203240A patent/AU2018203240B2/en active Active
- 2018-08-20 HK HK18110676.0A patent/HK1251170B/en unknown
- 2018-10-05 AU AU2018241168A patent/AU2018241168B2/en active Active
- 2018-12-05 JP JP2018228317A patent/JP6656345B2/ja active Active
-
2019
- 2019-01-08 US US16/242,139 patent/US10517847B2/en active Active
- 2019-01-15 CY CY20191100046T patent/CY1121480T1/el unknown
- 2019-03-29 US US16/370,443 patent/US10548872B2/en active Active
- 2019-05-23 JP JP2019096869A patent/JP6801045B2/ja not_active Expired - Fee Related
- 2019-10-16 CY CY20191101084T patent/CY1122177T1/el unknown
- 2019-10-23 HR HRP20191919TT patent/HRP20191919T8/hr unknown
- 2019-12-23 US US16/724,657 patent/US10792273B2/en active Active
-
2020
- 2020-01-31 US US16/779,015 patent/US11304924B2/en active Active
- 2020-10-05 US US17/063,372 patent/US11273143B2/en active Active
-
2022
- 2022-03-14 US US17/694,500 patent/US11786501B2/en active Active
-
2023
- 2023-09-22 US US18/371,722 patent/US12186301B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018143994A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| KR102435676B1 (ko) | 독성 알데히드 관련된 질병 및 치료 | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| JP2008513516A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2016540742A5 (https=) | ||
| JP2008513515A5 (https=) | ||
| WO2020072492A1 (en) | Benzamide derivatives as cgas-sting pathway agonists | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| AU2016323305A1 (en) | Hepatitis B core protein modulators | |
| DK2814489T3 (en) | COMPOSITIONS AND PROCEDURES FOR MODULATING SPECIFIC AMIDASES FOR N-ACYLETHANOLAMINES FOR USE IN THE THERAPY OF INFLAMMATORY DISEASES | |
| ES2861503T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
| CA2381090A1 (en) | Benzoic acid derivatives for the treatment of diabetes mellitus | |
| JP2014509647A5 (https=) | ||
| RU2018133288A (ru) | Комбинированные терапии для лечения спинальной мышечной атрофии | |
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| AR129378A1 (es) | Compuestos de indolinilo antivirales y usos de estos | |
| BR112015030315B1 (pt) | Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4 | |
| CA3024610A1 (en) | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer | |
| JP2018510138A5 (https=) | ||
| JP2021046404A5 (https=) | ||
| EA201070783A1 (ru) | 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний | |
| JP2016518448A5 (https=) | ||
| RU2019115059A (ru) | Модуляторы ror-гамма | |
| JP2015524483A5 (https=) |